Consensus Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:01 2024-04-23 pm EDT			5-day change	1st Jan Change
65.57 ^USD	-1.09%		-4.97%	-21.46%

Apr. 09	Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	MT
Apr. 05	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Evolution of the average Target Price on Cytokinetics, Incorporated

Price target over the last 5 years

History of analyst recommendation changes

168f.AzvJQ2WjX9Bqn43k9OHm6701Rax6dzn_lqPq-fI5wDM.RBamEQL7M6E19buDjKbfrcd-KJ82BUGx4emrprB8jwZVfKV0FdUbgRDS7g~9b5fff402f27b19d8995dba32cf0c0af

Analyst Recommendations on Cytokinetics, Incorporated

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	Apr. 09	MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	Mar. 06	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	Jan. 24	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	Jan. 19	MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market	Jan. 08	MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept	Dec. 27	MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating	Dec. 27	MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating	Dec. 27	MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating	Dec. 27	MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target	Nov. 09	MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated	Nov. 07	MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating	Nov. 03	MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating	23-10-20	MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating	23-10-09	MT
SVB Initiates Cytokinetics at Outperform	23-08-15	MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating	23-06-22	MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating	23-05-05	MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating	23-04-03	MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating	23-04-03	MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating	23-03-20	MT
UBS Adjusts Cytokinetics' Price Target to $67 From $66, Maintains Buy Rating	23-03-07	MT
Goldman Sachs Lowers Cytokinetics' Price Target to $48 From $56, Maintains Buy Rating	23-03-02	MT
Needham Adjusts Price Target on Cytokinetics to $60 From $58, Maintains Buy Rating	23-03-02	MT
Oppenheimer Adjusts Cytokinetics Price Target to $54 From $55, Maintains Outperform Rating	23-03-01	MT
BofA Securities Initiates Coverage on Cytokinetics With Neutral Rating, $49 Price Target	23-02-17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

65.57 USD

Average target price

91.34 USD

Spread / Average Target

+39.30%

High Price Target

122 USD

Spread / Highest target

+86.06%

Low Price Target

42.4 USD

Spread / Lowest Target

-35.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cytokinetics, Incorporated

Mizuho Securities
UBS
B. Riley
Truist Securities
Needham & Co.
HC Wainwright
Cantor Fitzgerald
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
Oppenheimer
BofA Securities
JMP Securities
Raymond James
Morgan Stanley
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research

Ratings for Cytokinetics, Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar